Establishment of Gemcitabine-resistant Mouse Pancreatic Ductal Adenocarcinoma Cell Line and Possible Therapeutic Agents

Read full text Summarise with VIRAT
Authors: Kumiko Miyashita, Kimihiro Yamashita, MAKOTO MIYOSHI, Takaaki Nishiyama, Yuki Ise, SHUN OHSAKA, 清水一也, Noriyuki Nishimura, Yuichi Hori
Cited by: 0
References: 18

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND/AIM: Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal due to gemcitabine (GEM) resistance. This study aimed to establish a clinically relevant immunocompetent model to identify novel mediators of acquired GEM resistance. MATERIALS AND METHODS: GEM selection to establish a line with reduced sensitivity (mPDAC-R). RESULTS: mPDAC-R exhibited sustained growth under GEM treatment, alongside enhanced invasiveness and metastatic potential. Transcriptomic profiling identified monoamine oxidase B (MAOB) as an up-regulated mediator. Pharmacological inhibition of MAOB significantly suppressed proliferation and tumor growth in both mPDAC-R and human PDAC cell lines. CONCLUSION: We established a novel GEM-resistant mPDAC model and identified MAOB as a promising therapeutic target. These findings provide a rationale for targeting MAOB-driven survival signals to overcome chemoresistance in refractory pancreatic cancer.

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Pancreatitis Pathology and Treatment Cancer Lipids and Metabolism

Publication details

Journal / source
Anticancer Research
Volume
46
Issue
4
Pages
1819–1831
Publication date
27 March 2026
Language
EN